Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site. The ad also hit a nerve with the pharma industry, lawmakers and some industry groups. The ad ...

Pharma lobby group The Pharmaceutical Research and Manufacturers of America (PhRMA) called HIMS’ commercial “a misleading Super Bowl ad that misrepresents their unapproved GLP-1 medicines.” ...

Hims & Hers Health has undeniably captured market attention and investor enthusiasm, fueled by a successful Super Bowl ad campaign and its strategic entry into the high-demand GLP-1 weight loss ...

The reaction: Last week, Senators Richard Durbin, a Democrat, and Roger Marshall, a Republican, criticized Hims & Hers' ad, writing in a letter to the FDA that the company didn’t include the ...

Earlier this month, Hims ran a Super Bowl ad touting the affordability of its weight loss drugs compared to those sold by big pharmaceutical companies. The ad sparked controversy for promoting ...

Hims & Hers Health ( NYSE: HIMS) shut down Apostrophe on Friday, the skincare business it acquired in 2019 for $190M. A ...

The “Check before you inject” ad specifically calls out compounded medications, which is the type that Hims & Hers manufactures and is not FDA approved. Novo Nordisk blasted its telehealth ...

Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticized the ...

Hims & Hers revealed that it will make its Big Game debut with a minute-long ad highlighting its compounded GLP-1 weight loss drug offerings. Set to Childish Gambino’s 2018 hit song “This Is America,” ...

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday as the company’s controversial Super Bowl ad on Sunday continued to ...